EUCTR2012-002940-26-NL进行中（未招募）1 期
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Newly diagnosed metastatic prostate cancer within 3 months prior to randomization with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
- •2. Distant metastatic disease documented by positive bone scan or metastatic lesions on computed tomography or magnetic resonance imaging scan
- •3. At least two of the following high-risk prognostic factors: Gleason score of >=8; presence of 3 or more lesions on bone scan; presence of measurable visceral (excluding lymph node disease) metastasis on CT or MRI scan based on RECIST 1.1
- •4. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2
- •5. Adequate hematologic, hepatic, and renal function
- •6. Agrees to protocol-defined use of effective contraception
- •Treatment Criteria for Crossover to the Open-label Extension Phase:
- •1. Subject is receiving study drug and is willing and able to provide written informed consent to crossover to open-label abiraterone acetate plus prednisone therapy
- •2. Adequate hepatic and safety laboratory assessments below within 4 weeks of OLE Phase Cycle 1 Day 1:
- •total bilirubin =1.5X upper limit of normal (ULN) (except for subjects with documented Gilbert’s disease in which case total bilirubin not to exceed 10X ULN)
- •alanine (ALT) and aspartate (AST) aminotransferase =2.5X ULN
- •serum potassium =3.5 mM. If a subject has a serum potassium level <3.5 mM, he could be given adequate potassium supplement and retested. Once the serum potassium level is =3.5 mM after adequate treatment with a potassium supplement, the subject would be eligible for enrollment in the OLE Phase.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 320
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 950
排除标准
- •1. Active infection or other medical condition that would make prednisone use contraindicated
- •2. Any chronic medical condition requiring a higher systemic dose of corticosteroid than 5 mg prednisone per day
- •3. Pathological finding consistent with small cell carcinoma of the prostate
- •4. Known brain metastasis
- •5. Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer; the following exceptions are permitted: up to 3 months of androgen deprivation therapy (ADT) with lutenizing hormone releasing hormone agonists or orchiectomy with or without concurrent anti-androgens prior to Cycle 1 Day 1; participants may have one course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 28 days prior to Cycle 1 Day 1, all adverse events associated with these procedures must be resolved at least to Grade 1 by Cycle 1 Day 1.
研究者
相似试验
进行中（未招募）
1 期
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002940-26-PTJanssen-Cilag International NV1,270
进行中（未招募）
1 期
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002940-26-DKJanssen-Cilag International NV1,270
进行中（未招募）
1 期
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002940-26-PLJanssen-Cilag International NV1,200
进行中（未招募）
1 期
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002940-26-FIJanssen-Cilag International NV1,270
进行中（未招募）
1 期
A Study of Abiraterone Acetate and Prednisone with Androgen Deprivation Therapy (ADT) versus ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic (spread of cancer cells from one part of the body to another) Hormone-naive Prostate CancerMetastatic Hormone-Naive Prostate Cancer (mHNPC)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002940-26-BEJanssen-Cilag International NV1,270